|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
Q3 FY2021
As of Jun 30, 2021
|
Q2 FY2021
As of Mar 31, 2021
|
Q1 FY2021
As of Dec 31, 2020
|
Q4 FY2020
As of Sep 30, 2020
|
Q3 FY2020
As of Jun 30, 2020
|
Q2 FY2020
As of Mar 31, 2020
|
Q1 FY2020
As of Dec 31, 2019
|
Q4 FY2019
As of Sep 30, 2019
|
Q3 FY2019
As of Jun 30, 2019
|
Q2 FY2019
As of Mar 31, 2019
|
Q1 FY2019
As of Dec 31, 2018
|
Q4 FY2018
As of Sep 30, 2018
|
Q3 FY2018
As of Jun 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and due from depository institutions | ||||||||||||||||||||
| Interest-bearing deposits in depository institutions | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| Investment securities available for sale, at fair value | ||||||||||||||||||||
| Equity securities, at fair value | ||||||||||||||||||||
| Investment securities held to maturity, at amortized cost | ||||||||||||||||||||
| Restricted stock, at cost | ||||||||||||||||||||
| Loans held-for-sale | ||||||||||||||||||||
| Loans receivable, net of allowance for loan losses | ||||||||||||||||||||
| Other real estate owned | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Fixed asset held-for-sale | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total Deposits | ||||||||||||||||||||
| FHLB advances | ||||||||||||||||||||
| Secured borrowing | ||||||||||||||||||||
| Other short-term borrowing | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Subordinated debt | ||||||||||||||||||||
| Advances from borrowers for taxes and insurance | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Shareholders’ Equity | ||||||||||||||||||||
| Preferred stock, $0.01 par value, 10,000,000 shares authorized, none issued | ||||||||||||||||||||
| Common stock, $0.01 par value, 50,000,000 shares authorized; 7,839,281 and 7,644,765 shares issued and outstanding, respectively, at March 31, 2023 and 7,828,344 and 7,633,828 shares issued and outstanding, respectively, at September 30, 2022 | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Unearned Employee Stock Ownership Plan (ESOP) shares | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost: 194,516 shares at December 31, 2022 and September 30, 2022 | ||||||||||||||||||||
| Treasury stock, at cost: 194,516 shares at March 31, 2023 and September 30, 2022 | ||||||||||||||||||||
| Total Shareholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Shareholders’ Equity |
Loading...
